Vanda earnings missed by $0.17, revenue fell short of estimates

Vanda (NASDAQ: VNDA) reported a significant second-quarter earnings miss, with EPS of $-0.46 against an estimated $-0.29 and revenue of $52.59 million falling short of the $55.1 million consensus. The company issued FY2025 revenue guidance of $210 million to $250 million, encompassing the $227.7 million analyst consensus. This financial underperformance follows a 17.20% decline in VNDA's stock over the past year, despite a recent 2.19% gain over three months, indicating continued operational challenges relative to market expectations.

Analysis

Vanda Pharmaceuticals (VNDA) reported a notable underperformance in its second-quarter results, with both earnings per share and revenue failing to meet analyst expectations. The company posted an EPS of $-0.46, a significant $0.17 below the consensus estimate of $-0.29, while revenue of $52.59 million also fell short of the projected $55.1 million. This operational miss aligns with the stock's longer-term trajectory, having declined 17.20% over the past 12 months, despite a minor 2.19% recovery in the last three months. Looking ahead, Vanda issued wide-ranging FY2025 revenue guidance of $210 million to $250 million. While the midpoint of this range is slightly above the analyst consensus of $227.7 million, the breadth of the forecast suggests considerable uncertainty. This mixed outlook is further corroborated by conflicting analyst EPS revisions in the last 90 days and an InvestingPro financial health score of only "fair performance," indicating that the company is not considered a top-tier undervalued opportunity by the platform's AI model.

Key Decisions for Investors

• Given the significant miss on both Q2 revenue and EPS, investors should exercise caution and closely monitor the company's ability to achieve its FY2025 revenue guidance, as the wide range indicates substantial operational uncertainty.
• The stock's 17.20% decline over the past year, coupled with a 'fair' financial health rating, suggests that the recent underperformance may be part of a continuing trend, warranting a thorough review of the company's fundamentals before increasing exposure.
• Considering the InvestingPro AI model did not identify Vanda as a top undervalued opportunity, investors should weigh the lack of a clear valuation catalyst against the recent negative earnings surprise and mixed analyst revisions.